You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Serum Hepcidin Immunoassay: Laboratory to Marketplace
SBC: INTRINSIC LIFESCIENCES Topic: NIDDKDESCRIPTION (provided by applicant): Disorders of iron metabolism are among the most common human diseases. During the last decade, rapid progress has been made in understanding the molecular basis of iron homeostasis and its disorders. The peptide hormonehepcidin has emerged as the master regulator of iron metabolism. Dysregulation of hepcidin is the principal or contributing factor in most syste ...
SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Serum Hepcidin Immunoassay: Laboratory to Marketplace
SBC: INTRINSIC LIFESCIENCES Topic: 300DESCRIPTION provided by applicant Disorders of iron metabolism are among the most common human diseases During the last decade rapid progress has been made in understanding the molecular basis of iron homeostasis and its disorders The peptide hormone hepcidin has emerged as the master regulator of iron metabolism Dysregulation of hepcidin is the principal or contributing factor in most syst ...
SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
TDP-43 aggregation inhibitors for the treatment of ALS
SBC: Aquinnah Pharmaceuticals Inc. Topic: 105Abstract Amyotrophic Lateral SclerosisALSis a universally fatal neurodegenerative disease that afflicts overout of everyindividualsProtein aggregation has been implicated as a primary driving force in ALS and multiple other neurodegenerative illnessesTDPis the principle component of the protein aggregates in ALSand TDPalso stands out as the only genetically defined ALS mutant gene that is also the ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer
SBC: PRIVO TECHNOLOGIES, LLC Topic: NCIPreceding Award: NCI Award 1R44CA192875-02 Project Summary: According to the Oral Cancer Foundation, about 50,000 people in the US will be newly diagnosed with oral cancer (OC) in 2017, causing 9,700 deaths[1]. OC is a severely neglected orphan disease with a lack of significant treatment advances in 4 decades[1]. Historically, OC has been present in heavy smokers and drinkers. However, more recen ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Rapid point of care test for Lyme serodiagnosis based on novel ultra sensitive de
SBC: IMMUNETICS, INC. Topic: NIAIDDESCRIPTION provided by applicant Lyme disease is the most prevalent vector borne disease in the U S with about cases per year reported by CDC and a range now covering states Early diagnosis and treatment of Lyme disease is important to prevent the disease from progressing to a systemic infection characterized by chronic arthritis carditis or neurological disorders Where a patien ...
SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Rapid, disposable, nucleic acid diagnostic device for multiplexed point of care f
SBC: MESA TECH INTERNATIONAL, INC. Topic: NIAIDDESCRIPTION provided by applicant Rapid and accurate identification of highly infectious and pathogenic disease is extremely important for the early forecast of outbreak risk and the effective deployment of medical and administrative countermeasures Unfortunately current diagnostics for use at the point of care POC are largely immunological assays that often lack adequate sensitivity speci ...
SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Riluzole Prodrugs for Melanoma and ALS
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: 102We have discovered a novel Type IIb prodrug of riluzole, trigriluzole (FC-4157, BVH-4157), which has the potential to substantially improve therapy for the treatment of the devastating condition of metastatic melanoma acting via a novel glutamatergic mechanism of action. While riluzole has shown promising efficacy in treating melanoma in patients, trigrilluzole is andgt;20X more potent than riluzo ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a urine test for the early detection of liver cancer
SBC: JBS SCIENCE INC Topic: 102Development of a urine test for the early detection of liver cancer The need to develop an effective method for detecting liver cancer is urgent. HCC, a primary liver cancer, is the third leading cause of cancer deaths worldwide and the fastest rising cancer in US. HCC has a 5-year survival rate of less than 15%, if detected early, the survival rate can be as high as 40%. The survival rate drops s ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas
SBC: VENATORX PHARMACEUTICALS INC Topic: NIAIDProject Summary This 3-year Phase II SBIR Application focuses on advancing the lead “ultra-broad-spectrum” carbapenem (USBC) VNRX-4099, possessing an unprecedented antibacterial spectrum of activity including MRSA, Enterobacteriaceae and Pseudomonas aeruginosa, to IND filing status. The UBSC VNRX-4099 will be paired with a proprietary in-house β-lactamase inhibitor VNRX-5133 (BLI) to protect ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
An Immunoprotectant for Marburg Virus
SBC: MAPP BIOPHARMACEUTICAL, INC. Topic: RDESCRIPTION provided by applicant Mortality rates associated with Marburg virus MARV outbreaks range from to over MARV is included by the Centers for Disease Control and Prevention as among the Category A agents or andquot high priority agents that pose a risk to national security andquot MARV not only causes acute and terrifying disease but it is relatively stable in wet or ...
SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health